Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J. Scott Eaddy"'
Autor:
Rachel J Church, Shelli J Schomaker, J Scott Eaddy, Germaine G Boucher, John M Kreeger, Jiri Aubrecht, Paul B Watkins
Publikováno v:
PLoS ONE, Vol 15, Iss 10, p e0240562 (2020)
Glutamate dehydrogenase (GLDH) is a liver-specific biomarker of hepatocellular damage currently undergoing qualification as a drug development tool. Since GLDH is located within the mitochondrial matrix, it has been hypothesized that it might also be
Externí odkaz:
https://doaj.org/article/4b07e64a012741b78f47489226cafa94
Autor:
Germaine Boucher, Rachel J. Church, John M. Kreeger, Paul B. Watkins, Shelli J. Schomaker, J. Scott Eaddy, Jiri Aubrecht
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 10, p e0240562 (2020)
PLoS ONE, Vol 15, Iss 10, p e0240562 (2020)
Glutamate dehydrogenase (GLDH) is a liver-specific biomarker of hepatocellular damage currently undergoing qualification as a drug development tool. Since GLDH is located within the mitochondrial matrix, it has been hypothesized that it might also be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd59f00575c24ff15ec8f7876db259a9
https://pubmed.ncbi.nlm.nih.gov/33035276
https://pubmed.ncbi.nlm.nih.gov/33035276
Autor:
William Valdar, Yvonne P. Dragan, Francis S. Wolenski, Merrie Mosedale, Patrick Kirby, J. Scott Eaddy, Yanwei Cai
Publikováno v:
Toxicology
Development of TAK-875 was discontinued when a small number of serious drug-induced liver injury (DILI) cases were observed in Phase 3 clinical trials. Subsequent studies have identified hepatocellular oxidative stress, mitochondrial dysfunction, alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d39feedd19b36319eda091e2f61b3622
https://doi.org/10.1016/j.tox.2021.152902
https://doi.org/10.1016/j.tox.2021.152902
Autor:
Natalie S. Holman, Jingtao Lu, Brenton R. Ware, O. Joseph Trask, Salman R. Khetani, Merrie Mosedale, Edward L. LeCluyse, Sharin E. Roth, William J. Brock, Paul B. Watkins, Kristina K. Wolf, J. Scott Eaddy
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology. 161(1)
Idiosyncratic drug-induced liver injury (IDILI) is thought to often result from an adaptive immune attack on the liver. However, it has been proposed that the cascade of events culminating in an adaptive immune response begins with drug-induced hepat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc2647cc23593229dfcd1d3882738a49
https://pubmed.ncbi.nlm.nih.gov/29029277
https://pubmed.ncbi.nlm.nih.gov/29029277
Autor:
Paul B. Watkins, Tim Wiltshire, Gregory R. Keele, William J. Brock, William Valdar, Robert W. Corty, Merrie Mosedale, Sharin E. Roth, Yuying Xie, Yunjung Kim, J. Scott Eaddy
Publikováno v:
Toxicological Sciences. :kfw269
Clinical trials of tolvaptan showed it to be a promising candidate for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) but also revealed potential for idiosyncratic drug-induced liver injury (DILI) in this patient population. To
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72c99d4bfe864c161ba4fdffde1b1715
https://doi.org/10.1093/toxsci/kfw269
https://doi.org/10.1093/toxsci/kfw269
Autor:
Gary A. Churchill, Paul B. Watkins, Thomas J. Urban, David W. Threadgill, Alison H. Harrill, Rachel J. Church, Daniel M. Gatti, J. Scott Eaddy, Shawn Ballard, Xi Yang, Qiang Shi, Nanye Long, Merrie Mosedale, Victor Navarro
Publikováno v:
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. 76
Consumer use of herbal and dietary supplements has recently grown in the United States and, with increased use, reports of rare adverse reactions have emerged. One such supplement is green tea extract, containing the polyphenol epigallocatechin galla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76df1d123c82c190275632f74c6592f0
https://pubmed.ncbi.nlm.nih.gov/25446466
https://pubmed.ncbi.nlm.nih.gov/25446466
Autor:
Mary F. Paine, Alison H. Harrill, Arlene S. Bridges, Paul B. Watkins, J. Ed. Hall, Richard R. Tidwell, C. Lisa Kurtz, Kristina D. DeSmet, Kristina K. Wolf, J. Scott Eaddy
Publikováno v:
Toxicological Sciences
DB289 is the first oral drug shown in clinical trials to have efficacy in treating African trypanosomiasis (African sleeping sickness). Mild liver toxicity was noted but was not treatment limiting. However, development of DB289 was terminated when se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec443d373ddee04e3e00d9535de2a598
